A Neutrophil-Biomimic Platform that Eradicates Metastatic Breast Cancer Stem-like Cells by Redox Modulation

A Neutrophil-Biomimic Platform that Eradicates Metastatic Breast Cancer Stem-like Cells by Redox Modulation

News Release, Redox Medicine 2023 , France – March 8, 2023

Metastasis accounts for 90% of breast cancer deaths, where the lethality could be attributed to the poor drug accumulation at the metastatic loci. The tolerance to chemotherapy induced by breast cancer stem cells (BCSCs) and their particular redox microenvironment further aggravate the therapeutic dilemma. To be specific, therapy-resistant BCSCs can differentiate into heterogeneous tumor cells constantly, and simultaneously dynamic maintenance of redox homeostasis promote tumor cells to retro-differentiate into stem-like state in response to cytotoxic chemotherapy.

Chu et al. develop a specifically-designed biomimic platform employing neutrophil membrane as shell to inherit a neutrophil-like tumor-targeting capability, and anchored chemotherapeutic and BCSCs-differentiating reagents with nitroimidazole (NI) to yield two hypoxia-responsive prodrugs, which could be encapsulated into a polymeric nitroimidazole core.

The platform can actively target the lung metastasis sites of triple negative breast cancer (TNBC), and release the escorted drugs upon being triggered by the hypoxia microenvironment. During the responsiveness, the differentiating agent could promote transferring BCSCs into non-BCSCs, and simultaneously the nitroimidazole moieties conjugated on the polymer and prodrugs could modulate the tumor microenvironment by depleting nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) and amplifying intracellular oxidative stress to prevent tumor cells retro-differentiation into BCSCs.

In combination, the BCSCs differentiation and tumor microenvironment modulation synergistically could enhance the chemotherapeutic cytotoxicity, and remarkably suppress tumor growth and lung metastasis. This work can potentially provide a new insight in to comprehensively treat TNBC and lung metastasis using a versatile platform.

Access full article.

Image Credits: Chu et al., Acta Pharmaceutica Sinica B, 2023

Redox Medicine 2023 will dedicate a whole session to "Redox Medicine & Cancer: Where we stand and where are we heading?"Abstract submission is open for any related research.

Media Contact:
Redox Medicine Society
This email address is being protected from spambots. You need JavaScript enabled to view it.

Redox Medicine 2023 Congress
June 21-23, 2023 - Paris, France
Website | LinkedIn | Facebook

Scientific News

  • 1
  • 2
Prev Next

read all news